NASDAQ · UTHR
United Therapeutics Corporation
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for UTHR: Nov 04, 2026
United Therapeutics Corporation Common Stock is expected to report earnings on 11/04/2026 before market open. The report will be for the fiscal Quarter ending Sep 2026. According to Zacks Investment Research, based on 6 analysts' forecasts, the consensus EPS forecast for the quarter is $5.85. The reported EPS for the same quarter last year was $7.16.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $5.85 | $6.70 | $4.40 | 6 |
| Dec 2026 | $6.91 | $7.96 | $6.43 | 6 |
| Mar 2027 | $7.32 | $8.49 | $6.33 | 3 |
| Jun 2027 | $5.89 | $7.40 | $3.94 | 3 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Zacks · RTTNews · Fintel · BNK Invest- Zacks · 3 h agoOmniAb, Inc. (OABI) Reports Q3 Loss, Tops Revenue EstimatesOmniAb, Inc. (OABI) delivered earnings and revenue surprises of 0.00% and +10.12%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Oct 29, 9:00 AM EDTEarnings Preview: Collegium Pharmaceutical (COLL) Q3 Earnings Expected to DeclineCollegium Pharmaceutical (COLL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks · Oct 28, 10:50 AM EDTLiquidia Gears Up to Report Q3 Earnings: What Can Investors Expect?LQDA's Q3 results will spotlight the impact of its legal settlement with UTHR, cash flow pressures, profitability prospects and pipeline progress.
- Zacks · Oct 28, 9:00 AM EDTAnalysts Estimate United Therapeutics (UTHR) to Report a Decline in Earnings: What to Look Out forUnited Therapeutics (UTHR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- RTTNews · Oct 28, 7:38 AM EDTUnited Therapeutics Gets FDA Clearance To Begin Trial Of Inhaled PAH Therapy(RTTNews) – United Therapeutics Corporation (UTHR) announced that the U.S. FDA has cleared the company to begin clinical testing of Treprostinil-Iloprost SMI, an investigational inhaled combination therapy for pulmonary arterial hypertension.
- Fintel · Oct 22, 10:24 AM EDTUnited Therapeutics Corporation Announces $2.0 billion Share Repurchase ProgramOn October 21, 2026, the Board of Directors of United Therapeutics Corporation approved a share repurchase program authorizing the purchase of up to $2.0 billion of the Company’s common stock. This authorization will remain in effect for a one-year period ending October 21,
- RTTNews · Oct 22, 9:22 AM EDTUnited Therapeutics Authorizes Additional $2 Billion Share Buyback Program(RTTNews) – United Therapeutics Corporation (UTHR) announced that its Board of Directors has approved a new share repurchase program authorizing the company to buy back up to $2 billion of its common stock through October 21, 2027.
- RTTNews · Oct 19, 9:51 AM EDTFDA Clears United Therapeutics' SUMMIT Study Of Treprostinil SMI In PH-COPD(RTTNews) – United Therapeutics Corp.(UTHR) announced that the U.S. Food and Drug Administration (FDA) has granted clearance under the company's investigational new drug application (IND) to proceed with the SUMMIT clinical trial of treprostinil SMI in pulmonary hypertension asso
- RTTNews · Oct 19, 7:23 AM EDTUnited: FDA Grants Clearance To Proceed With SUMMIT Trial Of Treprostinil SMI In PH-COPD(RTTNews) – United Therapeutics (UTHR) announced the FDA has granted clearance under the investigational new drug application to proceed with the SUMMIT clinical trial of treprostinil SMI in PH-COPD. The phase 2, 16-week, double blind SUMMIT study will evaluate the safety and tol
- Zacks · Oct 14, 12:38 PM EDTLQDA Settles UTHR Disputes for $380.7M, Limits Yutrepia LabelLiquidia settles six legal disputes with United Therapeutics, securing Yutrepia access for PAH patients but facing $380.7 million in payments and a narrower drug label.
- BNK Invest · Oct 14, 10:47 AM EDTXBI, IOVA, SYRE, UTHR: ETF Inflow AlertLooking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the State Street SPDR S&P Biotech ETF (Symbol: XBI) where we have detected an approximate $363.3 million dollar inflow — that's a 3.8% increase week
- Zacks · Oct 14, 10:40 AM EDTSGIOY or UTHR: Which Is the Better Value Stock Right Now?SGIOY vs. UTHR: Which Stock Is the Better Value Option?
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for United Therapeutics Corporation from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.